Akums introduces a room temperature treatment for sickle cell disease

Akums Drugs and Pharmaceuticals, a pharmaceutical company, has launched a room temperature stable oral suspension of Hydroxyurea designed to treat sickle cell disease (SCD). This new drug eliminates the need for cold storage, making it more accessible and affordable to SCD patients across India.

This product is manufactured in India and has been approved by the Drug Controller General of India. Akums says their new drug will be available for less than 1 percent of the cost of currently imported options.

SCD is a genetic blood disorder that causes severe pain and complications. It mainly occurs among tribal populations in India. Recognizing its importance, the Indian government has prioritized interventions for SCD.

Akums’ new product is designed for ease of use with oral syringes for accurate dosing for all age groups. “Akums is committed to providing affordable medications to SCD patients,” said Sanjeev Jain, Joint Managing Director, Akums Drugs and Pharmaceuticals. The company plans to offer the drug at a fraction of the cost of imported brands.

Traditionally, Hydroxyurea requires refrigeration, making it difficult to manage in some areas. Akums’ room temperature solution removes this barrier to treatment. Akums says they are committed to innovation and improving public health through the introduction of affordable and accessible medicines.

The current import price is around Rs 77,000 for the global brand of Hydroxyurea solution, which requires storage at 2 to 8 degrees Celsius. Akums has innovated a room temperature stable oral suspension of Hydroxyurea suitable for the needs of Indian patients.

First print: March 19, 2024 | 8:36 PM IST